Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics reported first quarter 2026 results and highlighted progress in its oncology pipeline. The company ended March 31, 2026 with $379.8 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028.
Collaboration revenue was $0 for the quarter, compared with $5.4 million a year earlier after the Gilead collaboration concluded. Research and development expenses were $33.5 million versus $36.4 million, while general and administrative expenses rose to $15.2 million from $11.5 million.
Net loss was $45.5 million, or $0.32 per share, compared with a net loss of $39.9 million, or $0.36 per share, in the prior-year period. The company reported encouraging early data from vopimetostat combination studies and outlined multiple 2026 clinical milestones. Two directors, Alexis Borisy and Kanishka Pothula, resigned without disagreements, and Sung Lee was appointed Lead Independent Director and chair of the Compensation Committee.
Tango Therapeutics, Inc. reported first-quarter 2026 results showing no collaboration revenue, compared with $5.4M a year earlier, after the earlier truncation of its Gilead research collaboration. Research and development expense was $33.5M, down from $36.4M, mainly from lower spend on deprioritized programs, while general and administrative expense rose to $15.2M from $11.5M on higher personnel and stock-based compensation.
The company recorded a net loss of $45.5M (net loss per share $0.32) versus $39.9M (net loss per share $0.36) a year ago. Cash, cash equivalents and marketable securities totaled $379.8M as of March 31, 2026, and management expects this to fund operations into 2028.
During the quarter, Tango raised $64.4M in gross proceeds via its at-the-market stock offering, issuing 5,148,151 shares, and also generated $17.6M from stock option exercises. The company is prioritizing its MTAP-deleted selective PRMT5 pipeline, advancing vopimetostat and TNG456, while deprioritizing TNG260 and TNG961.
Tango Therapeutics reports a Schedule 13G/A showing Adage Capital and affiliated reporting persons beneficially own 12,809,485 shares of Common Stock, equal to 8.98% of the class. The percentage is calculated using 142,688,851 shares outstanding as of February 26, 2026.
The statement attributes shared voting and dispositive power of 12,809,485 shares to Adage Capital Management, L.P., with reporting by Robert Atchinson and Phillip Gross. The filing is signed on May 13, 2026.
Farallon Capital filed Amendment No. 4 reporting its beneficial ownership in Tango Therapeutics, Inc. The filing states the Farallon Funds hold an aggregate of 9,097,411 Shares and 2,159,792 Pre-Funded Common Stock Purchase Warrants, each exercisable for one Share. The filing says the Warrants are subject to a Beneficial Ownership Limitation of 9.99% and that the Reporting Persons have assumed all Warrants are exercisable within 60 days for the purpose of computing beneficial ownership. The filing lists the Farallon funds, affiliated general partners, and individual Farallon managers and provides per-entity ownership counts and shared voting/dispositive power figures.
Tango Therapeutics, Inc. entered into a Separation Agreement and Release with former Chief Financial Officer Daniella Beckman on May 7, 2026, following the Board’s earlier decision that she would cease serving as CFO, principal accounting officer and principal financial officer effective April 15, 2026.
Under the agreement and her employment contract, Ms. Beckman will receive 12 months of severance pay at her current base salary, paid in installments, plus reimbursement of monthly COBRA premiums for up to 12 months. The company will also accelerate the vesting of her outstanding stock options and restricted stock units to reflect an additional 24 months of continued service from her May 1, 2026 employment end date and extend the post-termination stock option exercise period through August 31, 2026, in exchange for her signing a general release in favor of the company.
Tango Therapeutics Inc: This Schedule 13G shows FMR LLC (and Abigail P. Johnson as reported) beneficially owns 9,905,919 shares of Tango Therapeutics common stock, representing 6.9% of the class. The filing lists the issuer CUSIP 87583X109 and the issuer address in Boston. The filing states voting/dispositive power figures for FMR LLC and refers to Exhibit 99 and a power of attorney incorporated by reference.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sell transaction in company stock. On May 1, 2026, she exercised 27,000 stock options at an exercise price of $5.20 per share, acquiring the same number of common shares.
That day she made two open-market sales totaling 27,000 common shares: 1,100 shares at a weighted average price of $21.9964 per share and 25,900 shares at a weighted average price of $21.1931 per share. According to a footnote, these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
Tango Therapeutics, Inc.’s Chief Financial Officer Matthew Gall received new equity-based compensation. He was granted 40,000 shares of Common Stock in the form of restricted stock units, which represent rights to receive an equal number of shares as they vest over time.
The RSUs vest over three years: 13,200 units on or about May 10, 2027, 13,200 on or about May 10, 2028, and 13,600 on or about May 9, 2029, subject to continued service. He was also granted stock options for 240,000 shares of Common Stock at an exercise price of $20.98 per share, vesting 25% on April 15, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, also contingent on continued service.
Tango Therapeutics ownership update: This Amendment No. 2 to a Schedule 13G/A reports that Invus Public Equities directly holds 4,964,650 shares of common stock (approximately 3.5%) and Avicenna Life Sci Master Fund directly holds 692,455 shares (approximately 0.5%), each as of March 31, 2026.
The filing states calculations use 142,688,851 shares outstanding as of February 26, 2026. It discloses control relationships among Invus entities and that Raymond Debbane may be deemed to beneficially own 5,657,105 shares (about 4.0%) through related entities.
Tango Therapeutics director Lee Sung received new equity awards as part of board compensation. On April 29, 2026, Sung was granted 12,300 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on January 2, 2027, January 2, 2028, and January 2, 2029, contingent on continued board service.
Sung was also granted an option for 5,200 shares of common stock at an exercise price of $22.06 per share. This option vests in 36 substantially equal monthly installments over three years starting January 2, 2026, subject to continued service. Following the grants, Sung holds 22,300 shares of common stock directly and 5,200 stock options, reflecting routine non-employee director compensation rather than open-market trading.